Fernando L. Pagán, MD

Vice Chairman, Department of Neurology; Director, Movement Disorders Program; Medical Director, Georgetown University Hospital National Parkinsonism Foundation Center of Excellence; Medical Director, Translational Neurotherapeutics Program; Associate Professor, Department of Neurology, Georgetown University

Articles by Fernando L. Pagán, MD

Studies With Amantadine-DR/ER for Treatment of Dyskinesia

ByDaniel E. Kremens, MD, JD,Rajesh Pahwa, MD,Robert A. Hauser, MD, MBA,William Ondo, MD,Fernando L. Pagán, MD

April 25th 2023

The expert neurology panel discusses clinical trial data of amantadine-DR/ER in treatment of dyskinesia and OFF episodes in Parkinson disease.

Amantadine Formulations in Treatment of Dyskinesia in Parkinson Disease

ByDaniel E. Kremens, MD, JD,Rajesh Pahwa, MD,Robert A. Hauser, MD, MBA,William Ondo, MD,Fernando L. Pagán, MD

April 25th 2023

Drs William G. Ondo and Rajesh Pahwa analyze the pharmacokinetics of different formulations of amantadine for treatment of dyskinesia in Parkinson disease.

Promising Disease-Modifying Therapies in Parkinson Disease

ByKatelynn Getchell,Gonul Ozay, MD,Brian Nagle, MD,Irma Zhang, MD,Luke Lovelace,Emma Waldon, RN,Yasar Torres-Yaghi, MD,Fernando L. Pagán, MD

April 19th 2023

Despite years of use of gold-standard therapy levodopa, therapeutic development in Parkinson disease has advanced rapidly and expanded to numerous novel pathways and targets.

Treatment of Dyskinesia in Patients with Parkinson’s Disease

ByDaniel E. Kremens, MD, JD,Rajesh Pahwa, MD,Robert A. Hauser, MD, MBA,William Ondo, MD,Fernando L. Pagán, MD

April 18th 2023

Drs Rajesh Pahwa, Daniels Kremens and Fernando Pagan provide an overview of current treatment options for treatment of dyskinesia in patients with Parkinson’s Disease.

Challenges in Balancing Treatment of OFF Episodes and Dyskinesia in Parkinson Disease

ByDaniel E. Kremens, MD, JD,Rajesh Pahwa, MD,Robert A. Hauser, MD, MBA,William Ondo, MD,Fernando L. Pagán, MD

April 18th 2023

The expert panel highlights challenges in treatment of OFF episodes and dyskinesia together and long-term consequences of delaying treatment for dyskinesia in patients with Parkinson disease.

Diagnosis of Dyskinesia and Impact on Quality of Life of Patients With Parkinson Disease

ByDaniel E. Kremens, MD, JD,Rajesh Pahwa, MD,Robert A. Hauser, MD, MBA,William Ondo, MD,Fernando L. Pagán, MD

April 11th 2023

The expert panel shares strategies for accurate clinical diagnosis of dyskinesia in patients with Parkinson disease and discusses how dyskinesia may impact the quality of life.

Risk Factors for Dyskinesia in Patients With Parkinson Disease

ByDaniel E. Kremens, MD, JD,Rajesh Pahwa, MD,Robert A. Hauser, MD, MBA,William Ondo, MD,Fernando L. Pagán, MD

April 11th 2023

The expert neurology panel examines risk factors for development of dyskinesia in patients with Parkinson disease.

Pathophysiology of Dyskinesia in Parkinson Disease

ByDaniel E. Kremens, MD, JD,Rajesh Pahwa, MD,Robert A. Hauser, MD, MBA,William Ondo, MD,Fernando L. Pagán, MD

April 4th 2023

Drs William G. Ondo and Robert A. Hauser discuss the understanding of pathophysiology and clinical features of dyskinesia in patients with Parkinson disease.

Challenges With Parkinson Disease Treatments

ByDaniel E. Kremens, MD, JD,Rajesh Pahwa, MD,Robert A. Hauser, MD, MBA,William Ondo, MD,Fernando L. Pagán, MD

April 4th 2023

Drs Rajesh Pahwa and Daniel E. Kremens discuss challenges with Parkinson disease treatment and management of motor fluctuations, dyskinesia and OFF episodes in patients.

Use of Parkinson Disease Treatments and Identification of OFF Episodes in Clinical Practice

ByDaniel E. Kremens, MD, JD,Rajesh Pahwa, MD,Robert A. Hauser, MD, MBA,William Ondo, MD,Fernando L. Pagán, MD

March 28th 2023

The expert panel discusses advances in formulations of carbidopa/levodopa and identification of OFF and ON time in patients with Parkinson disease.

Treatment Options for Parkinson Disease

ByDaniel E. Kremens, MD, JD,Rajesh Pahwa, MD,Robert A. Hauser, MD, MBA,William Ondo, MD,Fernando L. Pagán, MD

March 28th 2023

Dr William G. Ondo provides an overview of available treatments and pharmacokinetic properties of different drugs for Parkinson Disease.

The Need for Education on Advanced Therapeutics for Movement Disorders: Fernando Pagan, MD; Yasar Torres-Yaghi, MD

ByFernando L. Pagán, MD,Yasar Torres-Yaghi, MD

October 21st 2021

The duo from MedStar Georgetown University Hospital detailed the need for education on Parkinson disease and movement disorder therapies, and the CME activities they’ve developed with the PMD Alliance to address those needs. [WATCH TIME: 5 minutes]

A Critical Evaluation of Disease-Modifying Strategies in Parkinson Disease

ByFernando L. Pagán, MD,Charbel Moussa, MBBS, PhD,Yasar Torres-Yaghi, MD

April 29th 2021

A trio of clinicians from Georgetown University explore the current status of disease-modifying therapies for individuals with Parkinson disease.

Fernando L. Pagán, MD

Articles by Fernando L. Pagán, MD

Studies With Amantadine-DR/ER for Treatment of Dyskinesia

Amantadine Formulations in Treatment of Dyskinesia in Parkinson Disease

Promising Disease-Modifying Therapies in Parkinson Disease

Treatment of Dyskinesia in Patients with Parkinson’s Disease

Challenges in Balancing Treatment of OFF Episodes and Dyskinesia in Parkinson Disease

Diagnosis of Dyskinesia and Impact on Quality of Life of Patients With Parkinson Disease

Risk Factors for Dyskinesia in Patients With Parkinson Disease

Pathophysiology of Dyskinesia in Parkinson Disease

Challenges With Parkinson Disease Treatments

Use of Parkinson Disease Treatments and Identification of OFF Episodes in Clinical Practice

Treatment Options for Parkinson Disease

The Need for Education on Advanced Therapeutics for Movement Disorders: Fernando Pagan, MD; Yasar Torres-Yaghi, MD

A Critical Evaluation of Disease-Modifying Strategies in Parkinson Disease

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Understanding Ocrelizumab’s Impact on Advanced Progressive MS: Insights From Dr. Gavin Giovannoni

FDA Clears Roche’s Elecsys pTau181 Test for Ruling Out Alzheimer-Related related Amyloid Pathology

Trofinetide Leads to Real-World Improvements in Rett Syndrome Symptoms, LOTUS Study Finds

How Multiple Sclerosis Affects Men

FDA Delays Review Deadline for Hunter Syndrome Agent Tividenofusp Alfa